These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 8852390)
1. The effect of renal insufficiency and hemodialysis on the pharmacokinetics of nalmefene. Matzke GR; Frye RF; Alexander AC; Reynolds R; Dixon R; Johnston J; Rault RM J Clin Pharmacol; 1996 Feb; 36(2):144-51. PubMed ID: 8852390 [TBL] [Abstract][Full Text] [Related]
2. Effects of liver disease on the disposition of the opioid antagonist nalmefene. Frye RF; Matzke GR; Schade R; Dixon R; Rabinovitz M Clin Pharmacol Ther; 1997 Jan; 61(1):15-23. PubMed ID: 9024170 [TBL] [Abstract][Full Text] [Related]
3. The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. Frye RF; Matzke GR; Jallad NS; Wilhelm JA; Bikhazi GB Br J Clin Pharmacol; 1996 Sep; 42(3):301-6. PubMed ID: 8877019 [TBL] [Abstract][Full Text] [Related]
4. Disposition of the opioid antagonist, nalmefene, in rat and dog. Murthy SS; Mathur C; Kvalo LT; Lessor RA; Wilhelm JA Xenobiotica; 1996 Jul; 26(7):779-92. PubMed ID: 8819305 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and dialysability of naltrexone in patients undergoing hemodialysis. Kambia NK; Dine T; Odou P; Bah S; Azar R; Gressier B; Dupin-Spriet T; Luyckx M; Brunet C Eur J Drug Metab Pharmacokinet; 2004; 29(4):225-30. PubMed ID: 15726882 [TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy. Kyhl LE; Li S; Faerch KU; Soegaard B; Larsen F; Areberg J Br J Clin Pharmacol; 2016 Feb; 81(2):290-300. PubMed ID: 26483076 [TBL] [Abstract][Full Text] [Related]
7. Nalmefene: intravenous safety and kinetics of a new opioid antagonist. Dixon R; Howes J; Gentile J; Hsu HB; Hsiao J; Garg D; Weidler D; Meyer M; Tuttle R Clin Pharmacol Ther; 1986 Jan; 39(1):49-53. PubMed ID: 3943269 [TBL] [Abstract][Full Text] [Related]
8. Nalmefene to prevent epidural narcotic side effects in pediatric patients: a pharmacokinetic and safety study. Rosen DA; Morris JL; Rosen KR; Nelson ER; Steelman RJ; Gustafson RA; Wilhelm JA; Chang CT; Thackara JW; Frye RF Pharmacotherapy; 2000 Jul; 20(7):745-9. PubMed ID: 10907964 [TBL] [Abstract][Full Text] [Related]
9. Evidence for the delivery of narcotic antagonists to the colon as their glucuronide conjugates. Simpkins JW; Smulkowski M; Dixon R; Tuttle R J Pharmacol Exp Ther; 1988 Jan; 244(1):195-205. PubMed ID: 3335997 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacokinetics of nalmefene after a single or multiple intravenous doses in Chinese healthy volunteers]. Liao RF; Zeng ZP; Wen YG Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1816-9. PubMed ID: 18971181 [TBL] [Abstract][Full Text] [Related]
11. Longer occupancy of opioid receptors by nalmefene compared to naloxone as measured in vivo by a dual-detector system. Kim S; Wagner HN; Villemagne VL; Kao PF; Dannals RF; Ravert HT; Joh T; Dixon RB; Civelek AC J Nucl Med; 1997 Nov; 38(11):1726-31. PubMed ID: 9374341 [TBL] [Abstract][Full Text] [Related]
12. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Ingman K; Hagelberg N; Aalto S; Någren K; Juhakoski A; Karhuvaara S; Kallio A; Oikonen V; Hietala J; Scheinin H Neuropsychopharmacology; 2005 Dec; 30(12):2245-53. PubMed ID: 15956985 [TBL] [Abstract][Full Text] [Related]
13. Effect of food on the pharmacokinetics of oxycodone and naltrexone from ALO-02, an extended release formulation of oxycodone with sequestered naltrexone. Gandelman K; Lamson M; Salageanu J; Bramson C; Matschke K; Malhotra B Clin Pharmacol Drug Dev; 2015 Sep; 4(5):370-6. PubMed ID: 27137146 [TBL] [Abstract][Full Text] [Related]
14. Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. Quelch DR; Mick I; McGonigle J; Ramos AC; Flechais RSA; Bolstridge M; Rabiner E; Wall MB; Newbould RD; Steiniger-Brach B; van den Berg F; Boyce M; Østergaard Nilausen D; Breuning Sluth L; Meulien D; von der Goltz C; Nutt D; Lingford-Hughes A Biol Psychiatry; 2017 Jun; 81(11):941-948. PubMed ID: 28216062 [TBL] [Abstract][Full Text] [Related]
16. Lipophilic nalmefene prodrugs to achieve a one-month sustained release. Gaekens T; Guillaume M; Borghys H; De Zwart LL; de Vries R; Embrechts RC; Vermeulen A; Megens AA; Leysen JE; Herdewijn P; Annaert PP; Atack JR J Control Release; 2016 Jun; 232():196-202. PubMed ID: 27107723 [TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics of aminoguanidine in end-stage renal disease patients on hemodialysis. Foote EF; Look ZM; Giles P; Keane WF; Halstenson CE Am J Kidney Dis; 1995 Mar; 25(3):420-5. PubMed ID: 7872319 [TBL] [Abstract][Full Text] [Related]
18. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]